Search Results - Maya H. Buch

Refine Results
  1. 1

    Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy by Lylia Ouboussad, Agata N. Burska, Andrew Melville, Maya H. Buch, Maya H. Buch

    Published in Frontiers in Medicine (2019-03-01)
    Get full text
    Article


  2. 2

    Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations by Sarah Horton, Maya H Buch, Paul Emery

    Published in Drug, Healthcare and Patient Safety (2010-08-01)
    Get full text
    Article


  3. 3

    Characterising subgroups of difficult-to-treat rheumatoid arthritis in real-world clinical settings by Yvonne Tan, George Rogers, Rudresh Shukla, Pauline Ho, Maya H. Buch

    Published in EULAR Rheumatology Open (2026-03-01)
    Get full text
    Article


  4. 4

    Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? by Vasco C. Romão, Edward M. Vital, João Eurico Fonseca, Maya H. Buch

    Published in Arthritis Research & Therapy (2017-10-01)
    Get full text
    Article


  5. 5

    High throughput multiplex immunoassays stratify patients according to symptom burden across the anti-Ro positive systemic autoimmune rheumatic disease spectrum by Sarah Dyball, Rudresh Shukla, Anastasia-Vasiliki Madenidou, Maya H. Buch, Ian N. Bruce, Ben Parker

    Published in Autoimmunity (2024-12-01)
    Get full text
    Article


  6. 6

    Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease by Maya H Buch, Sinisa Savic, Dennis G McGonagle, Mark Kacar, John Fitton, Andrew K Gough

    Published in RMD Open (2020-09-01)
    Get full text
    Article


  7. 7

    Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate by Roy Fleischmann, Boulos Haraoui, Maya H. Buch, David Gold, Gosford Sawyerr, Harry Shi, Annette Diehl, Kristen Lee

    Published in Rheumatology and Therapy (2022-12-01)
    Get full text
    Article


  8. 8

    What role do socioeconomic and clinical factors play in disease activity states in rheumatoid arthritis? Data from a large UK early inflammatory arthritis audit by Heidi Lempp, Maya H Buch, Sam Norton, Andrew Cope, Elena Nikiphorou, Mrinalini Dey, James Galloway, Maryam Adas

    Published in RMD Open (2024-09-01)
    Get full text
    Article


  9. 9

    Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis by Bernard Combe, Robin Besuyen, Antonio Gómez-Centeno, Tsukasa Matsubara, Juan José Sancho Jimenez, Zhaoyu Yin, Maya H. Buch

    Published in Rheumatology and Therapy (2022-10-01)
    Get full text
    Article


  10. 10

    Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study by Maya H Buch, Simon de Lusignan, Peter Irving, Kaivan Khavandi, James Galloway, Kevin Barrett, Monica Nijher, Ruth Nicholson

    Published in RMD Open (2020-09-01)
    Get full text
    Article


  11. 11

    Determinants of myocardial fibrosis in patients with immune-mediated inflammatory diseases by Nicholas Black, Joshua Bradley, Fardad Soltani, John P. Farrant, Josephine H. Naish, Matthias Schmitt, Maya H. Buch, Christopher A. Miller

    Published in Advances in Rheumatology (2025-06-01)
    Get full text
    Article


  12. 12

    Understanding the psychosocial determinants of effective disease management in rheumatoid arthritis to prevent persistently active disease: a qualitative study by Heidi Lempp, Maya H Buch, Sam Norton, Andrew Cope, Elena Nikiphorou, Mrinalini Dey, James Galloway, Ailsa Bosworth, Nkasi Stoll, Maryam Adas

    Published in RMD Open (2024-05-01)
    Get full text
    Article


  13. 13

    Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol by Maya H Buch, John D Pauling, Dinesh Khanna, Michael Hughes, Alain Lescoat, David Roofeh, Whitney Townsend, Robert D Sandler, François Zimmermann

    Published in BMJ Open (2021-03-01)
    Get full text
    Article


  14. 14

    Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT by Sarah Brown, Colin C Everett, Kamran Naraghi, Claire Davies, Bryony Dawkins, Claire Hulme, Christopher McCabe, Sue Pavitt, Paul Emery, Linda Sharples, Maya H Buch

    Published in Health Technology Assessment (2018-06-01)
    Get full text
    Article


  15. 15

    Subclinical Systemic Sclerosis Primary Heart Involvement by Cardiovascular Magnetic Resonance Shows No Significant Interval Change by Raluca B. Dumitru, Lesley‐Anne Bissell, Bara Erhayiem, Graham Fent, Ananth Kidambi, Giuseppina Abignano, John P. Greenwood, John Biglands, Francesco Del Galdo, Sven Plein, Maya H. Buch

    Published in ACR Open Rheumatology (2023-02-01)
    Get full text
    Article


  16. 16

    Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 rand... by Arne Yndestad, Maya H Buch, Carol A Connell, Kenneth Kwok, Ted Mikuls, Deepak L Bhatt, Jon T Giles, Christina Charles-Schoeman, Gary G Koch, Edward Nagy, Steven Ytterberg, Hyejin Jo, Karim Richard Masri

    Published in RMD Open (2024-05-01)
    Get full text
    Article


  17. 17

    Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha

    Published in Rheumatology and Therapy (2023-01-01)
    Get full text
    Article


  18. 18

    Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha

    Published in Rheumatology and Therapy (2022-10-01)
    Get full text
    Article


  19. 19

    Challenges in implementing treat-to-target in rheumatoid arthritis: a perspective from Brazilian rheumatologists by Adriana Maria Kakehasi, Angela Luzia Branco Pinto Duarte, Claiton Viegas Brenol, Diogo Souza Domiciano, Ieda Maria Magalhães Laurindo, Karina Rossi Bonfiglioli, Licia Maria Henrique da Mota, Maya H. Buch, Eduardo de Almeida Macêdo, Ricardo Machado Xavier

    Published in Advances in Rheumatology (2024-08-01)
    Get full text
    Article


  20. 20

    Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study by Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis

    Published in RMD Open (2024-10-01)
    Get full text
    Article


Search Tools: